Westmore · UDRP decision
WIPO · Case No. D2011-1817

Innovatis.com

TransferWIPO-indexed · informational, not legal advice

The Panel ordered transfer of <innovatis.com>. It found the domain identical to the Complainant’s INNOVATIS mark and confusingly similar to its + INNOVATIS mark. The Complainant established an unrebutted prima facie case that the Respondent lacked rights or legitimate interests. The Panel also accepted the Complainant’s supported and uncontradicted assertions that the domain, as presently registered to the Respondent, had been registered and was being used in bad faith, including through sponsored links associated with the Complainant’s field.

Outcome
Transfer
At a glance
Provider
WIPO
Outcome
Transfer
Decision date
2011-12-17
Panelist(s)
Karnell, Gunnar
Complainant
Roche Diagnostics GmbH
Respondent
TedKosher, Ted Kosher
Disputed domain(s)
innovatis.com
Domain history UDRP Intelligence

The timeline behind innovatis.com

Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.

Westmore reconstructs the full history behind innovatis.com — from public RDAP and the Internet Archive — as part of UDRP Intelligence:

Registration → decision → today timeline
Archived Wayback evidence of what the site showed
Registry bad-faith signals
The live current registrant
Available in UDRP Intelligence
Verified public record
Outcome & remedy
Complaint granted. Panel ordered transfer of innovatis.com.
Reverse Domain Name Hijacking
No RDNH raised.
Westmore Insight

The case illustrates the significance of distinguishing a domain’s original creation date from a later alleged change in registration or control. Although <innovatis.com> was created before the stated priority date of the Complainant’s trademarks, the Panel focused on the registration presently shown for the Respondent and accepted the supported, unrebutted account that the domain had remained under the Complainant’s control until 2011. The decision is also an example of a panel finding bad faith where the precise mechanism of the ownership change was unknown but the complainant supplied written evidence and the respondent offered no contrary account.

The three-part test
Identical or Confusingly SimilarMet
Rights or Legitimate InterestsMet
Registered and Used in Bad FaithMet

Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.

Case details
Provider
WIPO
Outcome
Transfer
Decision date
2011-12-17
Panel
Karnell, Gunnar
Full decision
5 min read · hosted by Westmore

WIPO Arbitration and Mediation Center ADMINISTRATIVE PANEL DECISION Roche Diagnostics GmbH v. TedKosher, Ted Kosher Case No. D2011-1817 1. The Parties The Complainant is Roche Diagnostics GmbH of Mannheim, Germany, internally represented. The Respondent is TedKosher, Ted Kosher of Luzern, Switzerland. 2. The Domain Name and Registrar The disputed domain name <innovatis.com> is registered with eNom. 3. Procedural History The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on October 21, 2011. On October 25, 2011, the Center transmitted by email to eNom a request for registrar verification in connection with the disputed domain name. On October 25, 2011, eNom transmitted by email to the Center its verification response confirming that the Respondent is listed as the registrant and providing the contact details. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”). In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on November 2, 2011. In accordance with the Rules, paragraph 5(a), the due date for Response was November 22, 2011. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on November 23, 2011. The Center appointed Gunnar Karnell as the sole panelist in this matter on December 8, 2011. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background According to the available WhoIs information, the disputed domain name <innovatis.com> was “created” on December 17, 1998. The Complainant has requested that the disputed domain name be transferred to the Complainant. 5. Parties’ Contentions A. Complainant The Complainant bases its claim on its trademarks INNOVATIS and + INNOVATIS registered as Community trademarks 001568773 and 002912541 respectively. First priority date is August 30, 2000. The disputed domain name is identical with the Complainant’s trademarks. The Complainant belongs together with Roche Pharmaceuticals and affiliated companies to one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics with global operations in more than 100 countries. Innovatis AG is now a fully integrated part of Roche Applied Science, a global business area of the Diagnostic Division of Roche. The disputed domain name was registered by Innovatis AG in 1998. It was used continuously as far back as the year 2005 and since the Complainant’s acquisition of Innovatis AG in 2009 together with that company. However, in September 2011, the Complainant found that the disputed domain name <innovatis.com> had been hijacked and brought under control of the Respondent without authorization of the Complainant. Documentary evidence proves that on January 6, 2011 the disputed domain name was still under the control of the Complainant, redirecting to its official webpage. The exact circumstances of the change of ownership of the entry are not known. The Respondent has no rights or legitimate interests in respect of the disputed domain name. Its website directs to a search engine composed of sponsored links referring to cell analysis, etc., in the area of the Complainant’s specializations. The only reason for its use by the Respondent is to benefit from the reputation of the Complainant’s trademarks and to illegitimately trade on its fame for commercial gain and profit. The Respondent’s registration, so as presently to own the disputed domain name, was made in bad faith and it is now being used in bad faith. From the Respondent’s Internet website stands out an intentional attempt for commercial purpose to attract Internet users to it by creating a likelihood of confusion with the Complainant’s trademarks as to the source, affiliation and endorsement of the Respondent’s website or of the products or services posted on or linked to it. The website at the disputed domain name refers to services offered by the Complainant (cell analysis). The Respondent may generate unjustified revenues for each “click-through” by on-line consumers of the sponsored links illegitimately capitalizing on the INNOVATIS and + INNOVATIS trademarks fame. B. Respondent The Respondent did not reply to the Complainant’s contentions. 6. Discussion and Findings The factual foundation of the Complainant’s contentions, as presented by the Complainant, while supporting its non contradicted Complaint by written evidence and reference to earlier UDRP case decisions, leads the Panel to the following conclusions: A. Identical or Confusingly Similar The disputed domain name is identical to the Complainant’s trademark INNOVATIS and it is confusingly similar to its trademark + INNOVATIS. B. Rights or Legitimate Interests The Complainant has established a prima facie case that the Respondent lacks rights or legitimate interests in respect of the disputed domain name and there has been no rebuttal by the Respondent. Nothing in the case file gives reason to believe that the Respondent has or has had any rights or legitimate interests in respect of the disputed domain name. C. Registered and Used in Bad Faith Absent any indication in the case file of elements that might tell against giving credence to the Complainant’s assertions regarding facts leading up to its conclusions that the disputed domain name <innovatis.com> has been registered, as presently shown for the Respondent, in bad faith and that it is now used in bad faith, the Panel confirms that the conditions about bad faith registration and bad faith use for a transfer of the disputed domain name to the Complainant are satisfied. 7. Decision For the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the disputed domain name <innovatis.com> be transferred to the Complainant. Gunnar Karnell Sole Panelist Dated: December 17, 2011

Source of record: WIPO . Reproduced for research; WIPO is the authoritative source.

Beyond the decision

What Westmore sees around innovatis.com

The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.

Connected to Westmore UDRP Intelligence
115,871 decisions · citations · panelists · parties · domain history
Eleanor · UDRP intelligence
Ask Eleanor about this decision
Ask Eleanor about this decision

A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.

Unlocking Eleanor for this case uses 1 of your complimentary Intelligence unlocks· 3 remaining

Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.

Westmore Professional · Unlock the intelligence

The decision is only the beginning.

You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.

Citation Intelligence
How this decision is cited and treated across the corpus.
Panelist Intelligence
The panel's tendencies, outcomes and reasoning patterns.
Domain History
Ownership chronology — creation vs. respondent acquisition.
Opposing-Party Research
Complainant, counsel and portfolio context.
Independent Case Review
Eleanor challenges your filing before the other side does.
Professional Matters
Open, research and manage matters end to end.
$395/month
Unlock Westmore Professional Annual & firm seats available · cancel anytime
Take the next step
Westmore UDRP · find the right service

Westmore UDRP records draw on WIPO-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.

Confidential buyer-side representation for premium-domain acquisitions.

LinkedIn
Insights
Briefs
Who Owns
Westmore
Research
UDRP
Support
Buyer-side only· Escrow-protected· NDA on request

© 2026 Westmore. All rights reserved.

A note on privacy

Westmore uses a few essential cookies to keep this site secure and running smoothly. Nothing about your identity or interest is ever sold or shared.